C4 Therapeutics (CCCC) Debt to Equity (2020 - 2023)

C4 Therapeutics' Debt to Equity history runs 4 years deep, the most recent figure standing at $0.04 for Q2 2023.

• In Q2 2023, Debt to Equity rose 37.01% year-over-year to $0.04; the TTM figure through Jun 2023 stood at $0.04 (up 37.01% YoY), while the FY2022 annual figure was $0.04, up 43.63% from the prior year.
• Debt to Equity was $0.04 for Q2 2023 at C4 Therapeutics, up from $0.04 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.04 in Q2 2023 to a low of -$0.06 in Q3 2020.
• Historically, Debt to Equity has averaged $0.03 across 4 years, with a median of $0.03 in 2022.
• Biggest YoY gain for Debt to Equity was 141.91% in 2021; the steepest drop was 22.8% in 2021.
• A 4-year view of Debt to Equity shows it stood at $0.04 in 2020, then dropped by 22.8% to $0.03 in 2021, then surged by 43.63% to $0.04 in 2022, then advanced by 11.4% to $0.04 in 2023.
• The last three Debt to Equity figures came in at $0.04 (Q2 2023), $0.04 (Q1 2023), and $0.04 (Q4 2022), per Business Quant data.